PyInvesting

Market research

SNN Smith & Nephew SNATS Inc

NYSE USD Healthcare

Latest close

29.7 —

As of 30 Oct 2026

Test a moving-average rule with historical data.

Market facts
Market cap
12B
P/E ratio
19.77
Analyst target
32.322
Dividend yield
2.7%
Beta
0.67

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 6 months ago

Smith & Nephew plc is currently in a long term uptrend where the price is trading 7.2% above its 200 day moving average.

From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.7.

Smith & Nephew plc's total revenue sank by 52.4% to $1B since the same quarter in the previous year.

Its net income has dropped by 40.2% to $174M since the same quarter in the previous year.

Finally, its free cash flow grew by 713.1% to $304M since the same quarter in the previous year.

Based on the above factors, Smith & Nephew plc gets an overall score of 3/5.